Amylx Pharmaceuticals Inc vs Southern Copper Corp — how do they compare? Amylx Pharmaceuticals Inc trades at $23.55 (market cap $2.64B), while Southern Copper Corp trades at $194.12 (market cap $164.21B). The key difference: Southern Copper Corp is far larger — about 62.2× Amylx Pharmaceuticals Inc's market cap, and Southern Copper Corp pays a 2.26% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SCCO | |
|---|---|---|
Market Cap | $2.64B | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $24.19 | $218.85 |
52-Week Low | $7.82 | $93.70 |
Enterprise Value | $2.39B | $165.50B |
Dividend Yield | — | 2.26% |
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Southern Copper (SCCO) trades at $193.14, down 3.48% on the day, amid a broader copper price pullback. The stock exhibits strong fundamentals with revenue growth from $13.42B in 2025 to a projected $15.8B in 2026 and robust profitability margins, including a net income margin of 35.87%. Recent quarters have consistently beaten EPS estimates, and technical indicators show a bullish trend with key support at $191. However, the stock trades at a premium valuation with a P/E of 29.18, above the analyst consensus price target of $153.64.
The outlook for SCCO is mixed; strong earnings growth and exposure to copper demand from AI and data centers present upside, but high valuation and reliance on volatile metal prices pose risks. Analyst sentiment is cautious with only 10.34% buy ratings, suggesting limited near-term upside from current levels despite solid operational performance.
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →